Phelps S F, Hauser M A, Cole N M, Rafael J A, Hinkle R T, Faulkner J A, Chamberlain J S
Department of Human Genetics, University of Michigan Medical School, Ann Arbor 48109-0618, USA.
Hum Mol Genet. 1995 Aug;4(8):1251-8. doi: 10.1093/hmg/4.8.1251.
Duchenne and Becker muscular dystrophy are caused by defects in the dystrophin gene, and are candidates for treatment by gene therapy. We have shown previously that overexpression of a full-length dystrophin cDNA prevents the development of dystrophic symptoms in mdx mice. We show here that this functional correction can be achieved by expressing the full-length muscle isoform at a lower level than is present in control animals. Gene therapy for DMD may necessitate the use of truncated dystrophin mini-genes to accommodate the limited cloning capacity of current-generation viral delivery vectors. We have constructed both murine and human mini-genes deleted for exons 17-48, and have demonstrated that expression of either mini-gene can almost completely prevent the development of dystrophic symptoms in transgenic mdx mice. These results suggest that viral-mediated expression of moderate levels of a truncated dystrophin could be an effective treatment for DMD.